S-Evans Biosciences Signs License for Menstrual Stem Cell Technology in China

Cryo-Cell International has signed an exclusive license agreement with S-Evans Biosciences (SEB), a privately-held stem cell and genomics technology company located near Shanghai in Hangzhou, Zhejiang Province, China. The partnership will allow the latter to market and manufacture proprietary C'elle menstrual stem cell technology including the processing and storage of menstrual stem cells (MenSCs) exclusively throughout mainland China.

It will also allow SEB to conduct scientific research studies using the technology to identify future potential therapeutic applications for a broad possible range of diseases. The license agreement will provide Cryo-Cell with future royalty fees from the processing and annual storage of menstrual stem cells.

In recent years, China has significantly increased its efforts in the field of stem cell research and practice. Currently, scientific research in the country primarily utilizes bone marrow and embryonic stem cells. Clinical applications of stem cells to treat conditions such as acute heart failure, acute liver failure and lower limb ischemia have been reported by many hospitals. A developing country with the largest population in the world, China's estimated total population is 1.3 billion of which women account for about half.

SEB believes that the future market opportunity for the C'elle service in China is potentially significant. "Stem cell research and development is well-recognized and fast-emerging in China. Our company believes that the proprietary technology of C'elle may provide women with the opportunity to collect and cryopreserve their own stem cells that have demonstrated considerable potential to be used in future therapies, and that are easily harvested from a non-controversial source," stated Dr Charlie Xiang, CEO.